Navigation Links
Duke to lead oversight of HIV laboratories worldwide
Date:11/16/2010

DURHAM, N.C. The National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), has awarded Duke University Medical Center up to $52.8 million over the next seven years to support the development, implementation and oversight of external quality assurance programs that monitor laboratories involved in HIV/AIDS research and vaccine trials around the world.

The project, External Quality Assurance Oversight Laboratory (EQAPOL), will be led by Thomas Denny, MSc, professor of medicine and chief operating officer of the Duke Human Vaccine Institute.

"This is critical work, and I believe the contract is a tribute to the extraordinary depth and reach of our research and support teams in the Duke Human Vaccine Institute," said Nancy Andrews, MD, PhD, dean of the Duke University School of Medicine.

Reliable and reproducible laboratory data are essential in evaluating treatments for HIV infection. Denny says there are several dozen laboratories globally that perform assays for HIV studies. "The absence of a single, centralized laboratory makes it imperative that strict quality assurance standards and protocols are in place. Patients, physicians and researchers all need to feel confident that a test on a blood sample performed in New York will yield the same results as the same test performed in London or South Africa as an example. Today, you might not find that."

The Division of Acquired Immunodeficiency Syndrome (DAIDS) at NIAID has requested Duke concentrate its work on several programs under the contract, including evaluation of processing and storage of blood from participants enrolled in NIAID supported clinical trials; evaluation of tests that measure immune responses to new therapies; coordination of efforts for new assays and new assay validation procedures, and participation in establishing and characterizing unique clade-specific HIV viral panels.

"Virus panels are used to determine how well new laboratory tests perform, but some of the panels developed for this work are more than 15 years old," says Denny. "As a result, current panels may not be truly reflective of which virus strains are circulating in the world today; they can change over time."

Denny says Clade B is the most frequent virus type in the Americas and parts of Asia while Clade C strains the most abundant genetic subtype in the world are most prevalent in southern Africa and Asia. "But the virus' propensity to mutate has led to the rise of some additional subtypes," says Denny. "We are now seeing rare subtypes like F, H, and O and some recombinant forms. It's important that any assays we use be appropriate for those strains, too."

Denny says reaching the goals of the contract will require the creation of several new support systems. One would be the development of central web repository at the Duke Clinical Research Institute that would to track all project data, including testing and quality assurance findings. The system would track deviation from approved protocols and generate lab performance standards over time.

The contract also calls for the creation of new blood and reagent banks and expanded resources at Duke to enable additional onsite work in processing, testing and shipping blood products, assays and reagents world-wide.

Denny has considerable experience in managing quality control and assurance in complex laboratory settings. He is the principal investigator of the NIH-NIAID Division of AIDS Immunology Quality Assurance Program and he has also served on a number of government panels established to formulate guidelines used in the diagnosis and treatment of patients with HIV/AIDS.

"Tom Denny has created a remarkable organization with unique expertise," said Barton Haynes, MD, director of the Duke Human Vaccine Institute and the Center for HIV/AIDS Vaccine Immunology. "The resources that he has brought to Duke will help HIV research at Duke and globally, as well."


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Actuaries Say Base Health Insurance Oversight on Actuarial Principles
2. Americas Prostate Cancer Organizations Offer Pointers to House Committee on Oversight and Government Reform
3. FDA Tightens Oversight of Home Medical Devices
4. Experts say direct-to-consumer genetic tests need innovative oversight
5. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
6. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
7. IDEXX Laboratories Elects Joseph Vumbacco as Director
8. Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories CRINONE(R) Progesterone Gel Product Line
9. Global Dental Laboratories Market to Exceed $14.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
10. Vinomis Laboratories Completes Additional Funding Round
11. ELLKAY Introduces Revolutionary Live Insurance Mapping Solution for Diagnostic Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
Breaking Medicine Technology: